Health
Regeneron’s Antibody Combination Therapy Reduces COVID-19 Mortality Risk – BioPharm International
RECOVERY trial results have shown that Regeneron’s investigational antibody combination therapy reduces the mortality risk for…
Results of the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial have shown that Regenerons investigational antibody combination therapy reduces the mortality risk for hospitalized patients with severe COVID-19 whose immune response has not started…
Continue Reading